Results of the 2014 Annual General Meeting

Results of the 2014 Annual General Meeting April 29, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announcesthat at its Annual General Meeting held at The Merrion Hotel, Upper MerrionStreet, Dublin 2, Ireland at 1.30 pm today, all resolutions contained in thenotice of meeting were decided by poll vote. The results of the poll are asfollows: Resolution For % Against % Votes Withheld (including cast as discretionary a % of votes) relevant shares in issueOrdinary Resolutions 1. To receive the Company's 400,965,756 98.95% 4,249,303 1.05% 68.80% 1,472,435Annual Report and Accountsfor the year ended December31, 2013. 2. To approve the 391,218,791 96.97% 12,224,728 3.03% 68.50% 3,243,975Directors' RemunerationReport. 3. To approve the 374,694,890 94.71% 20,926,142 5.29% 67.17% 11,066,462Directors' RemunerationPolicy. 4. To elect Dominic 404,467,447 99.82% 716,284 0.18% 68.80% 1,503,763Blakemore as a Director. 5. To re-elect William 400,680,783 98.89% 4,510,166 1.11% 68.80% 1,496,545Burns as a Director. 6. To re-elect Dr. Steven 404,565,517 99.84% 628,936 0.16% 68.80% 1,493,041Gillis as a Director. 7. To re-elect Dr. David 404,559,335 99.84% 630,570 0.16% 68.80% 1,497,589Ginsburg as a Director. 8. To re-elect David 398,241,506 98.74% 5,089,868 1.26% 68.48% 3,356,120Kappler as a Director. 9. To re-elect Susan Kilsby 391,916,029 96.72% 13,277,757 3.28% 68.80% 1,493,708as a Director. 10. To re-elect Anne Minto 400,967,152 99.45% 2,206,094 0.55% 68.45% 3,514,248as a Director. 11. To re-elect Dr. 404,554,602 99.84% 632,552 0.16% 68.80% 1,500,340Flemming Ornskov as aDirector. 12. To elect David Stout as 403,130,381 99.49% 2,060,469 0.51% 68.80% 1,496,644a Director. 13. To re-appoint Deloitte 401,119,071 98.99% 4,096,849 1.01% 68.80% 1,471,574LLP as the Company'sAuditor. 14. To authorize the Audit, 402,286,337 99.93% 284,166 0.07% 68.35% 4,116,991Compliance & Risk Committeeto determine theremuneration of theAuditor. 15. To approve the increase 404,516,894 99.86% 553,107 0.14% 68.78% 1,617,493in the Company's borrowingpowers. 16. To authorize the 373,096,915 92.54% 30,095,078 7.46% 68.46% 3,495,501allotment of shares.Special Resolutions 17. To authorize the 397,955,909 98.47% 6,202,843 1.53% 68.62% 2,528,742disapp99.95lication ofpre-emption rights. 18. To authorize market 404,995,809 99.95% 195,629 0.05% 68.80% 1,496,056purchases. 19. To approve the notice 342,512,195 84.53% 62,696,077 15.47% 68.80% 1,479,222period for generalmeetings. As at the record date, April 27, 2014, there were 588,965,802 ordinary sharesin issue (excluding shares held in treasury). Shareholders are entitled to onevote per share. A vote "withheld" is not a vote in law and is not counted inthe calculation of the proportion of votes validly cast. In accordance with Listing Rule 9.6.2R copies of the relevant resolutionspassed at the meeting have been submitted to the National Storage Mechanismand will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm. Tony GuthrieDeputy Company Secretary For further information please contact: Investor RelationsJeff Poulton [email protected] +1 781 482 0945Eric Rojas [email protected] +1 781 482 0999Sarah Elton-Farr [email protected] +44 1256 894157 MediaJessica Mann [email protected] +44 1256 894 280 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal andInternal Medicine and we are developing treatments for symptomatic conditionstreated by specialist physicians in other targeted therapeutic areas.

www.shire.com